Harmony Row Acquisition Co. is a Delaware corporation and direct wholly-owned subsidiary of GlaxoSmithKline LLC, itself an indirect wholly-owned subsidiary of GSK plc. Formed specifically to execute the acquisition of Nuvalent, Inc., the entity launched a cash tender offer in June 2026 to purchase all Class A and Class B shares of the oncology-focused biotechnology company at $124 per share. Upon completion, subject to conditions including regulatory approvals, the purchaser will merge with Nuvalent, which will continue as a direct wholly-owned subsidiary of GSK LLC.
None yet. When a new project in the record names Harmony Row Acquisition Co. as owner, partner or investor, it shows here.
Tender offer launched at $124 per share; requires majority of Class A shares tendered and HSR clearance; no guaranteed delivery; offer set to expire July 14, 2026.
Includes two late-stage ROS1 and ALK NSCLC inhibitors under FDA review for 2026 decisions, plus a HER2 candidate; expected to be accretive to profit from 2027 and funded by debt and cash.
